I recently happened upon the C-Span Booknotes' interview of John Abramson, MD, author of the new book, Overdosed America: The Broken Promise of American Medicine. 1 I was impressed with this former Robert Wood Johnson Fellow who currently is on the faculty of Harvard Medical School teaching primary care medicine. His experience as a family physician for 20 years obviously provides him with a diverse foundation to author such a work. During the interview, Dr. Abramson provided evidence with concrete examples of how commercialization has eroded American medicine; his primary targets included the medical literature, pharmaceutical industry, expensive treatments, and the Food and Drug Administration.
Based on his revealing interview, I ordered and read his book, and I would like to recommend it to the Hospital Pharmacy readership. At the heart of his premise is the description of the changing character and dynamic nature of American medicine and medical knowledge today -from optimizing patient care to seeking the greatest profit.
The business aspects and art of health care in America require astute leadership in all areas. Health professionals are acutely aware of the evolving nature of this issue in daily practice. In his book, Dr. Abramson offers much food for thought outlining several examples where evidence has been pitted against commercialization. One of the more intriguing parts of the book is an in depth discussion regarding the guidelines published by the 2001 National Cholesterol Education Program (NCEP). Dr. Abramson noted that despite the publication of a 284-page full report from the expert panel, most health professionals read only the summary report (specific evidencebased data are provided in the full report). Dr. Abramson suggests some guidelines may be supported by less evidence-based theory. For example, the updated guidelines appear definitive, "In recent trials, statin therapy reduced risk for CHD [congenital heart disease] in . . . women, in those with or without heart disease." According to Dr. Abramson, six references are cited in the full NCEP report as supportive of this statement. The guidelines also state that use in women is based on extrapolation of benefit from men of similar risk. However, he notes that the data addressing the primary prevention of heart disease in women with statins are supported by only 20 episodes of CHD in this population.
Numerous other examples are provided of extrapolation beyond assumed boundaries including Celebrex and Vioxx; hormone replacement therapy; direct to consumer advertising; treatment of osteoporosis, stroke, depression and social anxiety disorder, and type 2 diabetes. I highly recommend this book to provoke thoughtful discussion and raise interesting dialogue not only for health professionals who strive to be responsible members of expert panels but also for all consumers in the health care system.
